Vimal Elaichi faces Maharashtra FDA objection as surrogate ads remain a high-spend bet

Maharashtra’s FDA has objected to a Vimal Elaichi campaign featuring Bollywood actors, spotlighting continued surrogate marketing in pan masala and alcohol. With enforcement penalties typically modest versus media and celebrity costs, restricted-category ad spending still exceeds ₹1,000 crore annually.

— Source publishedWed, 16 Sept, 2026, 09:00 IST·First seen Wed, 16 Sept, 2026, 09:42 IST·Source ET Brand Equity

What happened

Vimal Elaichi · Surrogate advertising for pan masala and alcohol persists in India despite legal restrictions, aided by brand extensions, celebrity endorsements

Key facts

  • Penalties of up to ₹50 lakh under CCPA guidelines
  • Pan masala industry valued at ₹48,000 crore in India
  • Estimated ₹500 crore TV spend during IPL 2025
  • Annual restricted-category advertising spend exceeds ₹1,000 crore
  • Typical CCPA penalties of ₹10-20 lakh
  • Pan masala celebrity payouts are 25-50% higher than regular consumer categories

Why this matters

Compliance, legal-review and brand-safety capabilities gain strategic value as surrogate-ad enforcement intensifies, while partnerships tied to restricted-category marketers warrant closer diligence on regulatory and reputational exposure.

What to watch

  • Whether Maharashtra FDA issues a formal notice, monetary penalty, campaign-stop order or referral to another regulator.
  • ASCI rulings or Ministry of Information and Broadcasting guidance that explicitly classify the Vimal Elaichi campaign as surrogate advertising.
  • Evidence of coordinated action by other state FDAs, consumer-affairs authorities, COTPA enforcement bodies or police.
  • TV networks, cinema chains, Meta, Google, YouTube or OTT platforms removing, restricting or labeling similar ads.
  • Public responses from featured actors and whether brands renew, replace or reduce celebrity-led endorsements.
  • Any proposal to raise penalties, impose repeat-offender sanctions, or make media outlets and endorsers jointly liable.
  • Vimal may modify or pause the disputed creative while defending the advertised product as a legitimate elaichi or mouth-freshener line.
  • Competing pan masala and alcohol marketers will audit celebrity campaigns, product-pack visibility, disclaimers and distribution evidence for advertised extensions.
  • Broadcasters, OTT services and digital ad platforms may seek additional legal indemnities and category-clearance documentation before accepting restricted-category creative.
  • Celebrity endorsers and talent agencies may add morality, regulatory-exit and reputational-protection clauses to endorsement contracts.
  • FMCG and adjacent mouth-freshener brands may increase category-distinction messaging to avoid being grouped with surrogate advertisers.

Also reported by